Viridian Therapeutics partners with Kissei Pharmaceutical to advance treatments for thyroid eye disease in Japan, enhancing patient care and market potential.

Companies have scant financial incentive to develop new antibiotics. Will the NIH continue to support relevant research?

Dr. Falk Pharma, in cooperation with its fully-owned subsidiary Losan Pharma GmbH, a leading contract development and ...

Bon Natural Life Limited (Nasdaq: BON) ('BON' or 'the Company'), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch ...

According to the European Union, in 2024, EU exports of medicinal and pharmaceutical products increased by 13.5% compared ...

In an exclusive interview with Business Today, D. Sridhar Babu, Minister for Information Technology, Industries and Commerce, ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The U.S. Cryo Electron Microscopy Market set to exceed USD 1.13 billion by 2032, with accelerating adoption in drug discovery, academic research, and biopharmaceutical development.Austin, July 30, ...

Hopkins researcher Jean Fan and her team create open-source tools that help bridge the gap between academic discoveries and ...

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...

Medico-Legal Regulation Of Clinical Trials In IndiaMedical innovation, research and development are a necessary arm for the ...

Opportunities in traditional pharma companies with a focus on domestic formulations and US generic drugs are drying up ...